Jean-Pierre M. Ayoub

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study

Eric Winquist, Jennifer J. Knox, Jean-Pierre M. Ayoub et al. · Investigational New Drugs · 2006 · 131 citations

Medicine, Oncology, Pharmacology +15

An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer

Rocio García‐Carbonero, Fernando Rivera, Joan Maurel et al. · The Oncologist · 2014 · 64 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

Rahima Jamal, Réjean Lapointe, Eftihia Cocolakis et al. · Journal for ImmunoTherapy of Cancer · 2017 · 55 citations · Full text

Life Sciences, Immunology, Oncology +17

A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): CP12-0709/NCT00862784.

Rocio García‐Carbonero, Fernando Rivera, Jean-Pierre M. Ayoub et al. · Journal of Clinical Oncology · 2012 · 20 citations

Medicine, Oncology, Pharmacology +12